Borderline resectable pancreatic cancer: Certainties and controversies.
Borderline resectable pancreatic cancer
Chemotherapy
Neoadjuvant treatment
Pancreatic cancer
Pancreatic tumour
Radiotherapy
Journal
World journal of gastrointestinal surgery
ISSN: 1948-9366
Titre abrégé: World J Gastrointest Surg
Pays: United States
ID NLM: 101532473
Informations de publication
Date de publication:
27 Jun 2021
27 Jun 2021
Historique:
received:
28
02
2021
revised:
09
04
2021
accepted:
25
05
2021
entrez:
1
7
2021
pubmed:
2
7
2021
medline:
2
7
2021
Statut:
ppublish
Résumé
Borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is currently a well-recognized entity, characterized by some specific anatomic, biological and conditional features: It includes patients with a stage of disease intermediate between the resectable and the locally advanced ones. The term BR identifies a tumour with an aggressive biological behaviour, on which a neoadjuvant approach instead of an upfront surgery one should be preferred, in order to obtain a radical resection (R0) and to avoid an early recurrence after surgery. Even if during the last decades several studies on this topic have been published, some aspects of BR-PDAC still represent a matter of debate. The aim of this review is to critically analyse the available literature on this topic, particularly focusing on: The problem of the heterogeneity of definition of BR-PDAC adopted, leading to a misinterpretation of published data; its current management (neoadjuvant
Identifiants
pubmed: 34194610
doi: 10.4240/wjgs.v13.i6.516
pmc: PMC8223708
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
516-528Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: None of the authors have conflicts of interest.
Références
HPB (Oxford). 2019 Sep;21(9):1211-1218
pubmed: 30773450
Acta Oncol. 2008;47(3):413-20
pubmed: 17882555
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Med Oncol. 2018 May 30;35(7):100
pubmed: 29846849
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1196-205
pubmed: 26271395
JAMA Surg. 2016 Aug 17;151(8):e161137
pubmed: 27275632
Pancreatology. 2020 Mar;20(2):223-228
pubmed: 31839458
J Surg Oncol. 2010 Mar 15;101(4):315-20
pubmed: 20187063
Ann Surg Oncol. 2006 Aug;13(8):1035-46
pubmed: 16865597
Radiology. 2018 May;287(2):374-390
pubmed: 29668413
Gut Liver. 2021 May 15;15(3):466-475
pubmed: 32839360
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1221-8
pubmed: 26350371
Ann Surg Oncol. 2009 Jul;16(7):1751-6
pubmed: 19390900
Ann Surg Oncol. 2006 Jan;13(1):66-74
pubmed: 16372154
Pancreatology. 2019 Apr;19(3):449-455
pubmed: 30890308
J Gastrointest Surg. 2015 Jan;19(1):80-6; discussion 86-7
pubmed: 25091851
Pancreas. 2008 Jan;36(1):e26-32
pubmed: 18192876
Dig Surg. 2018;35(1):70-76
pubmed: 28482348
Br J Surg. 2005 May;92(5):539-46
pubmed: 15852419
J Clin Med. 2020 Apr 15;9(4):
pubmed: 32326559
Ann Surg. 2019 Jan;269(1):143-149
pubmed: 28857813
J Clin Pathol. 2016 Jun;69(6):463-71
pubmed: 26915370
Surgery. 2018 May;163(5):1090-1096
pubmed: 29395234
Pancreatology. 2018 Jan;18(1):2-11
pubmed: 29191513
BMC Cancer. 2017 Jul 27;17(1):505
pubmed: 28750659
J Gastrointest Oncol. 2016 Aug;7(4):547-55
pubmed: 27563444
Pancreatology. 2013 Sep-Oct;13(5):539-43
pubmed: 24075521
Medicine (Baltimore). 2014 Dec;93(27):e198
pubmed: 25501072
Surgery. 2016 Mar;159(3):893-900
pubmed: 26602840
J Clin Oncol. 2020 Jun 1;38(16):1763-1773
pubmed: 32105518
J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210
pubmed: 30865919
J Am Coll Surg. 2008 May;206(5):833-46; discussion 846-8
pubmed: 18471707
HPB (Oxford). 2017 Oct;19(10):927-932
pubmed: 28747265
World J Surg Oncol. 2019 Dec 31;18(1):1
pubmed: 31892339
BMC Cancer. 2020 Dec 2;20(1):1184
pubmed: 33267820
J Radiat Oncol. 2013 Dec;2(4):413-425
pubmed: 25755849
Ann Surg Oncol. 2021 Apr;28(4):2325-2336
pubmed: 32920720
Cancer. 2012 Dec 1;118(23):5749-56
pubmed: 22605518
PLoS Med. 2010 Apr 20;7(4):e1000267
pubmed: 20422030
Eur Radiol. 2017 Jul;27(7):3104-3116
pubmed: 27896469
Am J Clin Oncol. 2016 Jun;39(3):302-13
pubmed: 26950464
Oncologist. 2014 Mar;19(3):266-74
pubmed: 24569947
Surgery. 2014 Jun;155(6):977-88
pubmed: 24856119
Pancreatology. 2020 Sep;20(6):1131-1138
pubmed: 32739267
Lancet. 2001 Nov 10;358(9293):1576-85
pubmed: 11716884
Surgery. 2012 Nov;152(5):851-62
pubmed: 22682078
BMC Cancer. 2021 Mar 23;21(1):300
pubmed: 33757440
Br J Surg. 2018 Jul;105(8):946-958
pubmed: 29708592
Ann Surg. 2015 Jan;261(1):12-7
pubmed: 25599322
Pancreatology. 2016 Jan-Feb;16(1):28-37
pubmed: 26687001
Histopathology. 2013 Dec;63(6):841-51
pubmed: 24111684
Ann Surg Oncol. 2018 Mar;25(3):626-637
pubmed: 29214453
World J Surg Oncol. 2017 Oct 10;15(1):183
pubmed: 29017581
Ann Surg Oncol. 2009 Jul;16(7):1727-33
pubmed: 19396496
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1420-5
pubmed: 20056345
JAMA Surg. 2019 Oct 1;154(10):943-951
pubmed: 31411659
Ann Surg. 2016 Sep;264(3):457-63
pubmed: 27355262
Surgery. 2011 Sep;150(3):547-56
pubmed: 21621236
ANZ J Surg. 2020 Nov;90(11):2201-2210
pubmed: 32418344
Ann Surg Oncol. 2011 Mar;18(3):619-27
pubmed: 21213060
Ann Surg Oncol. 2013 Jul;20(7):2188-96
pubmed: 23247983
Eur J Surg Oncol. 2017 Jun;43(6):1061-1067
pubmed: 28389044
JAMA Oncol. 2020 Nov 1;6(11):1733-1740
pubmed: 32910170
Br J Cancer. 2016 Jul 26;115(3):290-6
pubmed: 27404453
J Gastrointest Surg. 2017 Nov;21(11):1793-1803
pubmed: 28849366
Ann Surg Oncol. 2014 May;21(5):1530-7
pubmed: 24473642
Ann Surg. 2018 Aug;268(2):215-222
pubmed: 29462005
J Surg Oncol. 2018 Apr;117(5):1073-1083
pubmed: 29448308
Ann Surg Oncol. 2013 Nov;20(12):3794-801
pubmed: 23838925